Delcath files new FDA application for chemo drug-device combination

Thu, 08/16/2012 - 2:39pm
Mass Device

Delcath files its 2nd new drug application in hopes of gaining FDA approval for the ChemoSat Generation 2 chemotherapy isolation system.

Delcath chemo delivery illustration

Delcath Systems (NSDQ:DCTH) filed a new FDA application for the latest iteration of its ChemoSat drug-device combination, the Generation 2 device, in treatment of patients with non-operable liver cancer.

Delcath's ChemoSat uses a system of tubes to localize the delivery of toxic chemotherapy agents by isolating the targeted organ — in this case, the liver — from the rest of the body's bloodstream.

Delcath must seek new drug approval for the melphalan hydrochloride the ChemoSat system uses to destroy cancerous tissue.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.